CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 49 resultados LastUpdate Última actualización 01/06/2020 [17:22:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 365 días/Published applications in the last 365 days



Página1 de 2 nextPage   por página


TOV 770 - An innovative ethyl alcohol, chlorite, hydrogen peroxide, tea tree oil extract (Melaleuca alternifolia) based anti- SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) viral surface sanitizer

NºPublicación: AU2020100545A4 28/05/2020

Solicitante:

WHOLESALE GROUP INT PTY LTD [AU]

Resumen de: AU2020100545A4

Abstract An innovative ethyl alcohol, chlorite, hydrogen peroxide, tea tree oil extract (Melaleuca alternifolia) based anti- SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) viral surface sanitizer comprising of a mixture of biocidal agents: (a) Ethyl alcohol (contains an ethyl group [saturated two carbon moiety] is an alkyl substituent derived from ethane (C 2H)) comprising of 65-70 % w/w of the composition; (b) Sodium and/or Calcium Hypochlorite [Na(CIO)/Ca(CIO) 2 ] comprising of 0.1% w/w of the composition; (c) 0.5% hydrogen peroxide comprising of 0.1% w/w of the composition (d) 0.01% Tea Tree Oil Extract (Melaleuca alternifolia) w/w of the composition.

traducir

DIGNOSTIC KIT AND WHOLE GENOME SEQUENCE IDENTIFICATION METHOD WHICH USE AMPLIFICATION OF WHOLE GENOME OF HUMAN ALPHA CORONAVIRUS

NºPublicación: WO2020105873A1 28/05/2020

Solicitante:

KOREA RES INST STANDARDS & SCI [KR]

Resumen de: WO2020105873A1

The present invention relates to a method for obtaining a whole genome sequence for determining the presence of infection by coronavirus, and a use thereof. A method, a kit and a composition of the present invention comprise a set of 11 universal primers capable of amplifying the genomic sequence of coronavirus, thereby enabling easy and rapid identification of the presence of a target virus in a sample and related diseases. In addition, through whole genome sequencing, mutations of novel coronavirus can be identified so as to be effectively used in the identification of novel viruses.

traducir

TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS

NºPublicación: US2020164058A1 28/05/2020

Solicitante:

KING ABDULAZIZ UNIV [SA]

Resumen de: US2020164058A1

An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.

traducir

CORONAVIRUS IMPACT ON THE WORLD ECONOMY PROBLEMS SOLVING: I invent the equation for solving the forecast of number of COVID-19 cases in the future so to help a country can re open the business as early as possible in the minimizes of COVID-19

NºPublicación: AU2020100564A4 21/05/2020

Solicitante:

PHAN HUNG THANH MR [AU]

Resumen de: AU2020100564A4

A method of solving problems on the coronavirus impact on the world economy by forecasting and controlling the spread of the virus.

traducir

Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments)

NºPublicación: RU2720614C1 12/05/2020

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE \u00ABNATSIONALNYI ISSLEDOVATELSKII TSENTR EPIDEMIOLO [RU]

Resumen de: RU2720614C1

FIELD: biotechnology, immunology, virology.SUBSTANCE: The invention relates to the field of biotechnology, immunology and virology, in particular to an immunobiological agent for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. Also, a method is disclosed for inducing specific immunity to the SARS-CoV-2 virus, comprising administering one or more immunobiological agents to the mammalian body for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. The invention allows to effectively induce an immune response against SARS-CoV-2 virus.EFFECT: the invention allows to effectively induce an immune response against SARS-CoV-2 virus.10 cl, 5 dwg, 12 tbl, 15 ex

traducir

SET OF SYNTHETIC OLIGONUCLEOTIDES FOR DETECTING OF CORONAVIRUS RNA

NºPublicación: RU2720713C1 12/05/2020

Solicitante:

RUBALSKIJ EVGENIJ OLEGOVICH [RU]

Resumen de: RU2720713C1

FIELD: medicine; biology.SUBSTANCE: invention refers to medicine and biology, namely to detection of SARS-CoV-2 coronavirus RNA in samples of biological material of human and animals, as well as in samples of environmental objects. Described is a set of synthetic oligonucleotides for detecting of SARS-CoV-2 coronavirus RNA includes a pair of primers selected from: 5'-GGTAAGAGTCATTTTGCTATTGGCC-3' and 5'-CTTGTAAAGTTGCCACATTCCTACG-3'; 5'-GTAAGAGTCATTTTGCTATTGGCC-3' and 5'-TTGTAAAGTTGCCACATTCCTACG-3'; 5'-TAAGAGTCATTTTGCTATTGGCC-3' and 5'-TGTAAAGTTGCCACATTCCTACG-3'; 5'-AAGAGTCATTTTGCTATTGGCC-3' and 5'-GTAAAGTTGCCACATTCCTACG-3'; 5'-AGAGTCATTTTGCTATTGGCC-3' and 5'-TAAAGTTGCCACATTCCTACG-3'; 5'-TGAGTGAAATGGTCATGTGTGG-3' and 5'-AGACCTTGAGATGCATAAGTGC-3'. From a pair of selected primers, one oligonucleotide can have a fluorescent label. A set of synthetic oligonucleotides for detecting of SARS-CoV-2 coronavirus RNA can additionally contain a fluorescent labeled oligonucleotide probe complementary or partially complementary to a nucleotide sequence flanked by a selected pair of primers.EFFECT: technical result of the invention consists in providing universal information value of detecting of SARS-CoV-2 RNA based on RT-PCR by eliminating the risk of obtaining false-negative results of RT-PCR in the presence of mutations in the amplified region of the SARS-CoV-2 genome.3 cl, 7 ex

traducir

2019 LAMP LAMP composition for detecting 2019 novel Coronavirus and uses thereof

NºPublicación: KR102109196B1 11/05/2020

Solicitante:

대한민국

Resumen de: KR102109196B1

본 발명은 2019 신종코로나바이러스(2019 novel Coronavirus) 검출용 LAMP(Loop-mediated isothermal amplification)용 조성물 및 이의 용도에 관한 것으로, 본 발명의 LAMP 조성물을 이용한 2019 신종코로나바이러스의 검출 방법은 시료로부터 별도의 핵산 추출 및 정제 과정 없이도 간단한 실시간 등온증폭기기만으로 분자진단 검사 결과를 현장에서 1시간 이내에 확인할 수 있으므로, 현장진단검사 등에 유용하게 활용될 수 있을 것이다.

traducir

Disinfectant bomb - Disinfectant dispersal system for small, medium and large areas. Disinfectant slow release spray for all modes of transport, homes and offices.

NºPublicación: AU2020100453A4 30/04/2020

Solicitante:

GIUMELLI COLIN BOYD MR [AU]

Resumen de: AU2020100453A4

Decontamination Dispersal Aerosol Unit for indoor hands-free use, said unit will come in range of sizes suitable for public and private transportation, office spaces, and private homes. The unit will deploy an aerosol variant of the disinfectant, covering all exposed areas (within specified coverage capabilities). This product will mitigate existing risks (e.g. viruses such as COVID-19) within essential services and industries allowing best opportunity for business as usual functions.

traducir

PROPOSED THERAPY TO REDUCE EFFECTS OF VIRAL INFECTIONS (may help with COVID 19) 16 Mar. 2020

NºPublicación: AU2020100400A4 23/04/2020

Solicitante:

THOMPSON EDGAR

Resumen de: AU2020100400A4

PROPOSED THERAPY TO REDUCE EFFECTS OF VIRAL INFECTIONS The disclosed proposed therapy to reduce effects of viral infections is a combination of lifestyle changes, vitamin supplements and prescription medicines that will reduce the impact of viral infections by boosting the body's immune system. The outcomes of adopting and implementing these strategies will amaze both young an older people. For example, younger people may only have to implement the lifestyle changes to have an extremely healthy outcome.

traducir

Inhibition Of TCR Signaling With Peptide Variants

NºPublicación: US2020123205A1 23/04/2020

Solicitante:

SIGNABLOK INC [US]

US_2019241618_A1

Resumen de: US2020123205A1

The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

traducir

NOVEL QUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

NºPublicación: WO2020080682A1 23/04/2020

Solicitante:

KOREA RES INST CHEMICAL TECH [KR]
PASTEUR INSTITUT KOREA [KR]
KOREA INST ORIENTAL MEDICINE [KR]

Resumen de: WO2020080682A1

The present invention relates to a novel quinolinone derivative, a preparation method therefor, and an antiviral composition containing same as an active ingredient. A novel quinolinone derivative provided in one aspect of the present invention exhibits an excellent inhibitory activity against a coronavirus infection, and thus can be effectively used as a pharmaceutical composition for preventing or treating a disease caused by a coronavirus infection, that is, MERS.

traducir

COVID-19 knockout DNA CoVID-19 suitable triple knockout DNAi remedy

NºPublicación: KR20200032050A 25/03/2020

Solicitante:

KIM SEUNG CHAN [KR]

Resumen de: KR20200032050A

다음은 중국 우한에서 출발 한 코로나 바이러스 전염병에 대한 삼중 녹아웃 DNA 안티센스 올리고머에 대한 다이어그램입니다. 이미 1 월 13 일에 진행된 무한 폐렴 바이러스 시퀀싱을 기반으로 한이 바이러스는 아직 조산되었지만 처방전이 포함되어 있습니다. 단일 가닥 특허는 2012 년에 확보되었다. 리포좀은 세포내 조달을 위해 단일 가닥 DNA를 수송하고 3 개의 부위에 결합하여 바이러스 게놈을 제거한다.

traducir

ISOXAZOLE DERIVATIVES AND PREPARATION PROCESS THEREOF

NºPublicación: WO2020040343A1 27/02/2020

Solicitante:

IL YANG PHARM CO LTD [KR]

KR_20200023034_A

Resumen de: WO2020040343A1

The present invention relates to an isoxazole derivative compound of Formula (1) useful as a substance for treating respiratory viral infectious disease caused by coronavirus, in particular, Middle East respiratory syndrome-coronavirus (MERS-CoV); a pharmaceutically acceptable derivative thereof; a preparation process of the same; and a pharmaceutical composition for the treatment of coronavirus infection comprising the above comopund as an active ingredient.

traducir

S A monoclonal antibody against S protein of MERS-CoV and use of the same

NºPublicación: KR20200020411A 26/02/2020

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

WO_2020036403_PA

Resumen de: KR20200020411A

The present invention relates to a monoclonal antibody which specifically recognizes spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein; or a functional fragment thereof. The monoclonal antibody or the functional fragment thereof includes one polypeptide sequence selected from a group consisting of the below polypeptide sequence. The monoclonal antibody comprises: a heavy chain including CDR1 region described as sequence number 1, CDR2 region described as sequence number 2, and CDR3 region described as sequence number 3; and a light chain including CDR1 region described as sequence number 4, CDR2 region described as sequence number 5, and CDR3 area described as sequence number 6. Therefore, the monoclonal antibody of the present invention can be applied to the diagnosis and treatment for the infection caused by MERS-CoV.

traducir

MONOCLONAL ANTIBODY AGAINST S PROTEIN OF MERS-CORONAVIRUS, AND USE OF SAME

NºPublicación: WO2020036403A1 20/02/2020

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

KR_20200020411_A

Resumen de: WO2020036403A1

The present invention relates to a monoclonal antibody capable of specifically recognizing a spike protein of Middle East respiratory syndrome coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment of the monoclonal antibody; and to a use of same, wherein the monoclonal antibody or a functional fragment thereof is characterized by comprising any one polypeptide sequence selected from the group consisting of the following polypeptide sequences, and wherein the monoclonal antibody consists of a heavy chain comprising a CDR1 region represented by SEQ ID NO: 1, a CDR2 region represented by SEQ ID NO: 2, and a CDR3 region represented by SEQ ID NO: 3, and a light chain comprising a CDR1 region represented by SEQ ID NO: 4, a CDR2 region represented by SEQ ID NO: 5, and a CDR3 region represented by SEQ ID NO: 6.

traducir

Fluorescent quantitative PCR detection method of human coronavirus and respiratory syncytial virus and application thereof

NºPublicación: CN110724764A 24/01/2020

Solicitante:

INST PATHOGEN BIOLOGY CAMS

Resumen de: CN110724764A

The invention provides primers and probes or a combination thereof of fluorescent quantitative PCR that can be used to detect diseases caused by human coronavirus and respiratory syncytial virus. In aspecific embodiment, the sequences of the primers and probes are as shown in SEQIDNOs: 1-3, and/or as shown in SEQIDNOs: 4-6, and/or as shown in SEQIDNOs: 7-9. The invention also provides applicationof the primers and probes or the combination thereof to preparation of reagents for detecting human coronavirus OC43, human coronavirus HKU1 and/or respiratory syncytial virus RSVB in samples.

traducir

New coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein

NºPublicación: CN110616198A 27/12/2019

Solicitante:

UNIV TSINGHUA
INST PASTEUR SHANGHAI CAS

Resumen de: CN110616198A

The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.

traducir

IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS)

NºPublicación: RU2709659C1 19/12/2019

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ ISSLEDOVATELSKIJ TSENTR EPIDEMIOLOG [RU]

Resumen de: RU2709659C1

FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, immunology and virology. Described is an immunobiological agent based on human recombinant adenovirus 5-th serotype or recombinant human adenovirus 26-th serotype, containing optimized expression in mammal cells consensus sequence of complete protective antigen S of MERS virus on the basis of sequences of protein S genes of modern strains of virus MERS 2015-2017 years with sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5. Method for using the immunobiological agent for inducing specific immunity to MERS-CoV. Method of using the immunobiological agent consists in the sequential introduction into the body of mammals of two different immunobiological agents based on human recombinant adenovirus of 5-th serotype or two different immunobiological agents based on human recombinant adenovirus of 26-th serotype with a period of more than 1 week, for inducing specific immunity to MERS-CoV. There is also developed a method for using the immunobiological agent consisting in consecutive introduction into an organism of mammals of any of the immunobiological agents based on human recombinant adenovirus of 5-th serotype and any of the immunobiological preparations based on human recombinant adenovirus 26-th serotype with a period of more than 1 week, for the induction of specific immunity to MERS-CoV, or in consecutive introduction into organism of mammals of any of immunobiological agents on

traducir

HBD2human beta-defensin 2 A composition for preventing or treating MERS-CoV virus comprising HBD2 human beta-defensin 2 or an fusion protein comprising epitope protein of MERS-CoV virus and the HBD2

NºPublicación: KR20190134578A 04/12/2019

Solicitante:

NAT UNIV CHONBUK IND COOP FOUND [KR]

Resumen de: KR20190134578A

The present invention relates to a composition for preventing or treating MERS-coronavirus comprising human beta-defensin 2 (HBD2) or epitope protein of MERS virus fused with a gene. In other words, HBD2 has effects of antiviral activity, innate immunity enhancement, and immunity enhancement.

traducir

MERS CORONAVIRUS VACCINE

NºPublicación: US2019351048A1 21/11/2019

Solicitante:

CUREVAC AG [DE]

WO_2018115527_A2

Resumen de: US2019351048A1

The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.

traducir

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein

NºPublicación: US2019351049A1 21/11/2019

Solicitante:

REGENERON PHARMA [US]

US_2017340728_A1

Resumen de: US2019351049A1

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

traducir

Primer probe mixed liquid and kit for detecting middle east respiratory syndrome corona virus (MERS-CoV)

NºPublicación: CN110468237A 19/11/2019

Solicitante:

DA AN GENE CO LTD OF SUN YAT SEN UNIV

CN_105624335_A

Resumen de: CN110468237A

The invention relates to primer probe mixed liquid and kit for detecting middle east respiratory syndrome corona virus (MERS-CoV), in particular to primer probe mixed liquid and kit for simultaneouslydetecting MERS-CoV UPE and N genes through a multiple real-time fluorescence polymerase chain reaction (PCR) technology. According to the kit, through a mode of separate detecting through multiple fluorescence channels, a multiple real-time fluorescence PCR mode is applied, thus the MERS-CoV UPE and N genes can be detected accurately and quickly, and the kit can be widely applied to multiple fields of MERS clinical early diagnosis, epidemic situation preventing and control, scientific research and the like.

traducir

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION

NºPublicación: US2019328865A1 31/10/2019

Solicitante:

NEW YORK BLOOD CENTER INC [US]

Resumen de: US2019328865A1

Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

traducir

An anti-MERS-CoV monoclonal antibody and use of the same

NºPublicación: KR20190122283A 30/10/2019

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

Resumen de: KR20190122283A

The present invention relates to a monoclonal antibody that specifically recognizes a protein of MERS-coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment thereof, and uses thereof, wherein the monoclonal antibody or functional fragment thereof comprises any one polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a CDR1 region as depicted in SEQ ID NO: 1, a CDR2 region as depicted in SEQ ID NO: 2 and a CDR3 region as depicted in SEQ ID NO: 3; and a light chain comprising a CDR1 region as depicted in SEQ ID NO: 4, a CDR2 region as depicted in SEQ ID NO: 5 and a CDR3 region as depicted in SEQ ID NO: 6.

traducir

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS

Nº publicación: PH12019500103A1 28/10/2019

Solicitante:

ABIOGEN PHARMA SPA [IT]

US_2019336456_A1

Resumen de: PH12019500103A1

The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.

traducir

Página1 de 2 nextPage por página

punteroimgVolver